Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 100.525 USD -0.36%
Market Cap: 249.5B USD

Net Margin
Merck & Co Inc

29.6%
Current
19%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
29.6%
=
Net Income
19B
/
Revenue
64.2B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Merck & Co Inc
NYSE:MRK
252.3B USD
30%
US
Eli Lilly and Co
NYSE:LLY
967.6B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
488.8B USD
27%
CH
Roche Holding AG
SIX:ROG
249.5B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
211.7B GBP
16%
CH
Novartis AG
SIX:NOVN
206.5B CHF
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.1B USD
16%
FR
Sanofi SA
PAR:SAN
103.7B EUR
21%
No Stocks Found

Merck & Co Inc
Glance View

Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.

MRK Intrinsic Value
125.841 USD
Undervaluation 20%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
29.6%
=
Net Income
19B
/
Revenue
64.2B
What is the Net Margin of Merck & Co Inc?

Based on Merck & Co Inc's most recent financial statements, the company has Net Margin of 29.6%.

Back to Top